4 active not recruiting, 4 completed, 2 recruiting, 1 unknown. 10 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Active not recruiting 3, Recruiting 2, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Unknown 1 |
Follow Salivary Gland Carcinoma: new trials by email Literature Review of Salivary Gland Carcinoma trials Research Report on Salivary Gland Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Abiraterone With Dalpiciclib in Salivary Gland Carcinoma abiraterone combined with dalpiciclib - Salivary Gland Carcinoma | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 36 | 2026-10-01 | 2026-09-11 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone) - Salivary Gland Carcinoma, Precision Therapy | Phase 2 | Recruiting | Peking Union Medical College | 39 | 2023-08-15 | 2026-04-02 |
| Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment - Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | Mayo Clinic | 174 | 2022-02-16 | 2026-07-16 |
| Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma Goserelin Acetate, Pembrolizumab - Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Manish Patel | 20 | 2019-05-30 | 2026-07-10 |
| Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy - Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung | Phase 1 / Phase 2 | Completed | University of Washington | 20 | 2019-01-15 | 2023-12-29 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck Nivolumab - Salivary Gland Carcinoma, Metastatic Cancer | Phase 2 | Completed | UNICANCER | 98 | 2017-03-24 | 2022-01-11 |
| Cell-free Tumor DNA in Head and Neck Cancer Patients Liquid biopsy - Head and Neck Cancer, Head and Neck Neoplasms | Not applicable | Unknown | Christian von Buchwald | 500 | 2017-02-01 | 2021-09-21 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) pembrolizumab - Advanced Cancer, Anal Carcinoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 1609 | 2015-12-18 | 2025-09-22 |
| Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma pazopanib - Salivary Gland Carcinoma | Phase 2 | Completed | UNICANCER | 72 | 2013-08-26 | 2019-10-29 |
Salivary Gland Neoplasms (12) · Cholangiocarcinoma (3) · Laryngeal Neoplasms (3) · Mouth Neoplasms (3) · Thyroid Neoplasms (3) · Uterine Cervical Neoplasms (3) · Anus Neoplasms (2) · Bile Duct Neoplasms (2) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Hypopharyngeal Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Neuroendocrine Tumors (2)
Mouth Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Salivary Gland Diseases (12) · Stomatognathic Diseases (12) · Head and Neck Neoplasms (10) · Mouth Neoplasms (9) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Adenocarcinoma (4)
Carboplatin (2) · Goserelin (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Platinum (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Albumin-Bound Paclitaxel (1) · Androgen Receptor Antagonists (1) · CTLA-4 Antigen (1) · Cisplatin (1) · FAPI-46 (1) · Fluorodeoxyglucose F18 (1) · Fulvestrant (1)
UNICANCER (2) · Actuate Therapeutics Inc. (1) · Christian von Buchwald (1) · Jonsson Comprehensive Cancer Center (1) · Klus Pharma Inc. (1) · Manish Patel (1) · Mayo Clinic (1) · Merck Sharp & Dohme LLC (1) · Peking Union Medical College (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · University of Washington (1)
United States (6) · China (2) · France (2) · Denmark (1)
Christian Von Buchwald, MD, DMSc (1) · Cristina Rodriguez (1) · Glenn J Hanna, MD (1) · Jeremie Calais (1) · Jie Zhang (1) · Joel Mr Guigay, Pr (1) · Jordi Rodon Ahnert, MD, PhD (1) · Manish Patel, MD (1) · Scott C. Lester, M.D. (1) · Yue He, M.D. (1)
PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36748723, PMID 39886516, PMID 39979665, PMID 40121391, PMID 41920388
2015 (1), 2016 (1)